Injectable Drug Delivery conference 2018

SMi Group16 - 17 May 2018, London, UK.
The SMi Group are thrilled to present the launch of Injectable Drug Delivery Conference 2018. The event is taking place in central London on 16th and 17th May 2018, with two pre-conference workshops occurring on 15th May 2018.

The Global Injectable Drug Delivery Market is expected to reach $789.7 billion USD by 2024, with a compound annual growth rate (CAGR) of 11.5% during the period of 2017 to 2024, according to Research Markets Reports. Therefore, this conference will aim to discuss the key developments in this field and the latest technological advancements.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Jean-René Authelin, Global Head, Pharmaceutical Engineering, Sanofi
  • Joel Richard, Senior Vice President, Peptides Development, Ipsen

Featured speakers:

  • Anand Subramony, Vice President, Novel Product Technologies, MedImmune
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • Maxime Gaillot, Senior Device Engineer, Roche
  • Pierre Goldbach, Senior Principal Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche AG
  • Fie Falck Larsen, Senior Usability Engineer, Injection Devices, Global Research and Development, LEO Pharma
  • Francesco Malavasi, Medical Device Quality Device Risk Manager, Novartis

Featured highlights:

  • Review device designs for a future portfolio
  • Explore risk management options for combination products
  • Hear how companies are tackling compatibility challenges of biologics with high volume injectors
  • Learn how vial-based novel delivery technologies can overcome complex dosing regiments
  • Discover how nanosystems can help address present and future challenges in injectable peptide delivery

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/injectable-drug-delivery

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...